TCRT | tickerfilter.com

Fundamental analysis

16%

Profitability 0%

Dept financing 32%

Liquidity 50%

Performance 20%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-4.52%

1 Month

-8.64%

3 Months

-9.76%

6 Months

-31.16%

1 Year

-9.76%

2 Year

192.49%

Key data

Stock price

$1.48

P/E Ratio

0.00

DAY RANGE

$1.46 - $1.50

EPS

-$0.82

52 WEEK RANGE

$0.58 - $5.62

52 WEEK CHANGE

-$13.45

MARKET CAP

5.156 M

YIELD

N/A

SHARES OUTSTANDING

16.013 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

2.23

PUBLIC FLOAT

AVERAGE 10 VOLUME

$12,935

AVERAGE 30 VOLUME

$9,798

Company detail

CEO: Kevin S. Boyle
Region: US
Website: alaunos.com
Employees: 40
IPO year: 2006

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR. The company was formerly known as ZIOPHARM Oncology, Inc.

TCRT - Alaunos Therapeutics, Inc.